- Home
- FRGE vs DMAC Comparison
FRGE vs DMAC Comparison
Compare FRGE & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRGE
- DMAC
- Stock Information
- Founded
- FRGE 2014
- DMAC 2000
- Country
- FRGE United States
- DMAC United States
- Employees
- FRGE N/A
- DMAC N/A
- Industry
- FRGE Computer Software: Prepackaged Software
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- FRGE Technology
- DMAC Health Care
- Exchange
- FRGE Nasdaq
- DMAC Nasdaq
- Market Cap
- FRGE 262.8M
- DMAC 310.1M
- IPO Year
- FRGE N/A
- DMAC N/A
- Fundamental
- Price
- FRGE $19.75
- DMAC $6.69
- Analyst Decision
- FRGE Buy
- DMAC Strong Buy
- Analyst Count
- FRGE 5
- DMAC 3
- Target Price
- FRGE $35.50
- DMAC $12.33
- AVG Volume (30 Days)
- FRGE 108.9K
- DMAC 250.2K
- Earning Date
- FRGE 11-04-2025
- DMAC 11-12-2025
- Dividend Yield
- FRGE N/A
- DMAC N/A
- EPS Growth
- FRGE N/A
- DMAC N/A
- EPS
- FRGE N/A
- DMAC N/A
- Revenue
- FRGE $90,840,000.00
- DMAC N/A
- Revenue This Year
- FRGE $32.73
- DMAC N/A
- Revenue Next Year
- FRGE $21.74
- DMAC N/A
- P/E Ratio
- FRGE N/A
- DMAC N/A
- Revenue Growth
- FRGE 14.78
- DMAC N/A
- 52 Week Low
- FRGE $6.60
- DMAC $3.19
- 52 Week High
- FRGE $24.90
- DMAC $7.49
- Technical
- Relative Strength Index (RSI)
- FRGE 62.19
- DMAC 48.33
- Support Level
- FRGE $16.16
- DMAC $6.50
- Resistance Level
- FRGE $22.20
- DMAC $7.10
- Average True Range (ATR)
- FRGE 1.31
- DMAC 0.30
- MACD
- FRGE 0.41
- DMAC -0.04
- Stochastic Oscillator
- FRGE 61.72
- DMAC 30.37
About FRGE Forge Global Holdings Inc.
Forge Global Holdings Inc is a financial service platform created to serve the needs of the private market. It provides marketplace infrastructure, data services, and technology solutions for private market participants. The company offers a trusted trading platform, proprietary data and insights to inform investment strategies, along with custody services to help companies, shareholders, institutions and accredited investors confidently navigate and transact in the private market.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.